Purinergic Signaling and the Postmenopausal Heart

Recruiting now

Conditions studied: Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction

In brief

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Key facts

Study ID

NCT06015776

Run by

Beth Israel Deaconess Medical Center

People needed

500

Starts

2019-07-01

Expected to finish

2030-06-01

Last updated by the study team

2026-03-20

Who can join

Age: 30 and older, up to 88. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing cardiac surgery under cardiopulmonary bypass.

You may not qualify if…

• Refusal to participate
• Emergency surgery
• Pre-existing heart block
• Preexisting atrial fibrillation
• Redo surgery
• Estrogen or hormone replacement therapy
• History of chronic heart failure
• History of major kidney disease

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.